Biological mechanisms of bevacizumab-associated adverse events.
about
Anti-angiogenic agents in metastatic colorectal cancerPractical management of bevacizumab-related toxicities in glioblastomaThe cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeletonInhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.Angiogenesis inhibitors: current strategies and future prospects.Immunological Approaches in the Treatment of Metastasized Breast CancerNovel points of attack for targeted cancer therapy.Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancerAntiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathwayModeling efficacy of bevacizumab treatment for metastatic colon cancer.Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.Role of bevacizumab therapy in the management of glioblastoma.Trials of bevacizumab in breast cancer--a safety review.Safety of bevacizumab in patients with metastatic breast cancer.The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cellsInhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP-2 expressionAdnectin-targeted inhibitors: rationale and results.[Adverse events related to bevacizumab and the management principles in non-small cell lung cancer].
P2860
Q26801911-611C38C8-EF0A-4BD5-8937-4FD81966273FQ27015852-9E8871A2-3856-486F-A598-74A9A006E4BEQ28116193-72AE6FB4-0329-4AD9-980E-E0627033E38AQ33584252-F402A71D-B118-404A-94CB-9788584FC85EQ34056376-9DAA730E-0E2A-4355-963A-4666EB8A48D2Q34140043-983F5BF6-CD58-4166-9D64-5EFDF8D4037EQ35023279-70656D72-2BCA-40F8-8FA9-848755231DEDQ35120530-AD611B27-03BE-4EAC-9691-8AB99B817400Q35122078-E87506CE-2698-4B72-AF75-C8E05CE8011CQ36316939-07B1F621-6DD5-490E-A337-B4EE88530157Q36845505-E8A8250B-F45A-4F4F-91E1-D7A80C04D2B8Q37687310-B0915D61-F85B-4209-800E-2679E8E3A8A3Q37824254-9CBC3DDA-E68C-45A8-B51B-6391324CEDEEQ37887823-4B69193C-5C79-43E9-A1F6-2FD37DC98404Q37903602-ACA04E03-A8EA-49A3-B91B-5A6EFB6D8614Q41364759-7CFE3B6C-BF55-4169-B1A9-822B5A66CFC3Q42290642-44DEA930-5B2C-4D8A-A90D-8A12E8247414Q54267763-60259B83-E1FF-4DCB-8B99-1C2DCA56A934Q55433803-76CADE03-FF96-40AF-9212-A771A0173885
P2860
Biological mechanisms of bevacizumab-associated adverse events.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biological mechanisms of bevacizumab-associated adverse events.
@en
Biological mechanisms of bevacizumab-associated adverse events.
@nl
type
label
Biological mechanisms of bevacizumab-associated adverse events.
@en
Biological mechanisms of bevacizumab-associated adverse events.
@nl
prefLabel
Biological mechanisms of bevacizumab-associated adverse events.
@en
Biological mechanisms of bevacizumab-associated adverse events.
@nl
P2860
P356
P1476
Biological mechanisms of bevacizumab-associated adverse events.
@en
P2093
Gerald M Higa
Jame Abraham
P2860
P304
P356
10.1586/ERA.09.68
P577
2009-07-01T00:00:00Z